- The USPTO issues six patents to Vical (VICL) covering its DNA vaccines for herpes simplex virus type 2 (HSV-2) containing specific gene sequences and formulated with its Vaxfectin adjuvant. The IP is jointly owned by the company and the University of Washington.
- The patents cover composition of matter of plasmid DNA vaccines encoding several HSV-2 antigens, including envelope and tegument viral proteins, separately or in combination, and formulated with the Vaxfectin adjuvant.
- The new patents add to Vical's patent estate that is based on its discovery that administering genetic sequences without the use of viral vectors will result in expression of the proteins encoded by the sequences.
Vical secures six patents covering HSV-2 vaccines
Recommended For You
About FRTX Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
FRTX | - | - |
Fresh Tracks Therapeutics, Inc. |